Best Practices for Lyme Disease Clinical Trials
- Apr 15
- 8 min read
Updated: 5 days ago
Field Guide for Research Teams and Patient-Centered Organizations
This paper is part of the CYNAERA Lyme Library, a growing resource, bult to help redefine how chronic Lyme is researched, diagnosed, counted and treated.
By Cynthia Adinig
Key Findings and Summary
Lyme disease clinical trials have historically failed to produce consistent, real-world outcomes due to narrow cohort selection, overreliance on acute infection models, and endpoints that do not reflect patient experience. This paper identifies core structural gaps in Lyme research, including failure to account for co-infections, immune variability, and environmental triggers. It proposes a CYNAERA-aligned framework centered on stabilization, adaptive trial design, and longitudinal data capture.
Key recommendations include:
Prioritizing stabilization before intervention to reduce harm and improve signal clarity
Designing multi-stage, adaptive trials that reflect disease progression
Expanding endpoints to include functional recovery, and relapse reduction outcomes
Integrating environmental and terrain-based data into study design
Using digital biomarkers and simulation modeling to improve trial accuracy and reproducibility
This framework supports more accurate, patient-centered, and scalable Lyme disease research.
1. Frame the Study Around Persistence and Stabilization, Not Just Acute Infection
Lyme disease is increasingly recognized as a condition that can extend beyond acute infection into a persistent, multi-system illness involving immune dysregulation, neurological symptoms, and functional impairment (Rebman and Aucott, 2020; National Academies of Sciences, Engineering, and Medicine, 2025).
Define remission using patient-centered outcomes such as sustained functional recovery and reduction in relapse cycles
Include post-treatment and persistent symptom cohorts rather than excluding them
Prioritize stabilization before aggressive interventions to reduce risk
2. Prioritize Deep Screening for Co-Infections and Comorbid Conditions
Lyme disease frequently coexists with other infections and chronic conditions that influence disease trajectory and treatment response.
Participants should be screened and stratified for:
Co-infections such as Babesia microti and Bartonella species (Diuk-Wasser et al., 2016)
POTS and dysautonomia
Mast Cell Activation Syndrome (MCAS)
Autoimmune and connective tissue disorders such as EDS
Neurological involvement including cognitive dysfunction and neuropathy
Failure to account for these variables contributes to heterogeneous outcomes and reduced interpretability.
3. Design a Multi-Stage, Adaptive Trial Architecture
Lyme disease progression is variable and often nonlinear. Trial design should reflect this complexity.
Stage 1: Stabilization
Address inflammation, autonomic instability, and environmental triggers
Provide supportive interventions such as hydration, pacing, and symptom stabilization
Establish a true baseline before intervention
Stage 2: Targeted Intervention
Apply antimicrobial, immunomodulatory, or metabolic therapies
Stratify treatment arms based on co-infections and symptom clusters
Use adaptive protocols to respond to patient variability (FDA, 2019)
Stage 3: Maintenance and Relapse Prevention
Monitor flare triggers including stress, environmental exposures, and exertion
Evaluate durability of response over time
Use flexible stopping rules and adaptive trial designs
4. Use Endpoints That Reflect Real-World Disease Behavior
Traditional endpoints often fail to capture the lived experience of Lyme disease.
Primary endpoints
Sustained symptom stability over 3–6 months
Reduction in relapse frequency and severity
Functional restoration, including cognitive and physical capacity
Secondary endpoints
Neurological symptom improvement
Autonomic function (e.g., heart rate variability, orthostatic tolerance)
Quality of life and healthcare utilization
Persistent Lyme research highlights fatigue, pain, and cognitive dysfunction as central outcomes, reinforcing the need for broader endpoint selection (Chandra et al., 2013; Geebelen et al., 2022).
5. Integrate Environmental and Terrain-Based Data
Environmental exposures influence disease expression and symptom severity.
Track air quality, mold exposure, temperature, and humidity
Assess individual sensitivity to environmental triggers
Incorporate terrain-based modeling into data analysis
Ignoring environmental variability introduces noise and reduces reproducibility.
6. Integrate AI and Digital Biomarkers
Lyme disease symptoms fluctuate over time, making static assessments insufficient.
Use wearable devices to monitor heart rate, sleep, and activity levels
Capture real-time symptom variability and early flare signals
Apply machine learning models to identify patterns across subgroups
Digital health research supports the use of wearable biosensors for capturing physiologic changes over time (Li et al., 2017; Dunn et al., 2018).
7. Use Simulation Modeling Before Trial Launch
Trial failure in Lyme disease is often driven by poor cohort design and unmodeled variability.
Use simulation tools to model heterogeneity, relapse patterns, and dropout risk
Optimize inclusion criteria and treatment arms before enrollment
Improve safety and reduce cost through pre-trial modeling (Ioannidis, 2016)
8. Engage Ethical Oversight with Patient Representation
Patients with persistent Lyme symptoms have historically been excluded from research design.
Include patient advocates in trial oversight and design
Allow flexible participation protocols for individuals with fluctuating illness
Provide transparent risk communication for experimental interventions
This improves both recruitment and ethical integrity.
9. Plan for Real-World Implementation and Global Scalability
Lyme disease presents differently across regions and care systems.
Develop protocols that can be implemented in primary care settings
Design diagnostics for both early and late-stage disease
Plan for global adaptation and licensing across healthcare systems
10. Document Complexity and Preserve Negative Findings
Incomplete reporting has slowed progress in Lyme research.
Publish both positive and negative outcomes
Document subgroup variability and treatment response differences
Maintain clear rationale for all trial decisions
Transparent reporting strengthens future research and prevents repeated failure.
Why Traditional Lyme Disease Trials Fail
Despite extensive research, Lyme disease trials often produce inconsistent or limited results due to structural design limitations. Many studies rely on acute infection models and assume that bacterial clearance resolves disease, despite evidence of persistent symptoms in a subset of patients (Talbot et al., 2023; Rebman and Aucott, 2020). Strict cohort selection further limits applicability, as patients with co-infections, complex symptom profiles, or seronegative presentations are often excluded (Rebman et al., 2021).
Trial designs frequently fail to capture the dynamic nature of Lyme disease, where symptoms fluctuate and relapse patterns are common. Longitudinal approaches have been recommended to better understand disease progression (National Academies of Sciences, Engineering, and Medicine, 2024). Endpoints are often misaligned with patient experience, focusing on short-term changes rather than sustained functional improvement. Studies consistently show that fatigue, cognitive dysfunction, and reduced quality of life remain central concerns (Chandra et al., 2013).
Neurological and autonomic involvement, including small fiber neuropathy and dysautonomia, are also underrepresented in trial design despite growing evidence of their relevance (Novak et al., 2019; Adler et al., 2024). Finally, the lack of continuous data collection limits the ability to detect meaningful patterns over time. Digital biomarkers and wearable technologies offer a pathway to address this gap (Li et al., 2017).
Summary
Lyme disease trials fail when they treat Lyme as a static, short-term infection rather than a complex, multi-system condition. Improved outcomes require adaptive design, broader cohort inclusion, longitudinal data, and endpoints that reflect real-world disease burden. These gaps are further explored through The Eve Research Project, an ongoing research program capturing real-world patient data across hormonal life stage, immune activity, and environmental exposure. The findings highlight how current clinical trials often fail to account for variability in disease expression, leading to inconsistent outcomes across key patient populations.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Adler, B.L., Chokshi, D.A. and Katz, S.D. (2024) ‘Dysautonomia following Lyme disease’, Frontiers in Neurology, 15.
Chandra, A.M., Wormser, G.P., Marques, A.R., Latov, N. and Alaedini, A. (2013) ‘Health-related quality of life in post-treatment Lyme disease syndrome’, Quality of Life Research, 22(1), pp. 75–84.
Diuk-Wasser, M.A., Vannier, E. and Krause, P.J. (2016) ‘Coinfection by Babesia microti and Borrelia burgdorferi’, Trends in Parasitology, 32(1), pp. 30–43.
Dunn, J., Runge, R. and Snyder, M. (2018) ‘Wearables and the medical revolution’, Personalized Medicine, 15(5), pp. 429–448.
FDA (2019) Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry.
Geebelen, L., et al. (2022) ‘Post-treatment Lyme disease symptoms’, BMC Infectious Diseases, 22.
Ioannidis, J.P.A. (2016) ‘Why most clinical research is not useful’, PLoS Medicine, 13(6).
Li, X., Dunn, J., Salins, D., et al. (2017) ‘Digital health and wearable biosensors’, PLoS Biology, 15(1).
National Academies of Sciences, Engineering, and Medicine (2024) Innovative Approaches to Accelerating Lyme Research.
National Academies of Sciences, Engineering, and Medicine (2025) Pathways for Lyme-Associated Chronic Illness Research.
Novak, P., Wormser, G.P., Marques, A.R., et al. (2019) ‘Small fiber neuropathy in post-treatment Lyme disease’, PLoS ONE, 14(2).
Rebman, A.W. and Aucott, J.N. (2020) ‘Post-treatment Lyme disease’, Frontiers in Medicine, 7.
Rebman, A.W., et al. (2021) ‘Symptom heterogeneity in Lyme disease’, BMJ Open, 11.
Talbot, N.C., Nguyen, M. and Aucott, J.N. (2023) ‘Lyme disease treatment developments’, Antibiotics, 12(9).
Comments